| Revenue growth | 15% YoY growth in Q1 FY27. |
|---|---|
| Margins | Gross margin at 50%; EBITDA margin stable at 11%. |
| Demand visibility | Strong growth in premium-value Paddy and Maize segments. |
| Management confidence | High, focused on dream-product basket and supply chain. |
Growth
Q1 Revenue at ₹3,228 Mn (+15% YoY); PAT at ₹327 Mn (+12% YoY); EBITDA margin steady at 11%.
Outlook
Strong growth in Maize (+59% value) and Paddy (+34% value) segments; maintains capacity of 25,000MT.
Risks
Seasonal demand and agri-climatic conditions; 31% increase in finance costs impacting net margins.
Last quarter's promises, checked
Delivered
- Guided 20% Cotton growth → delivered 22.35% (= BEAT)
- Guided 20-25% Paddy growth → delivered 25% (= BEAT)
- Guided 15-20% Top line growth → delivered 19% (= BEAT)
Partly delivered
- Guided EBITDA margin upward trend → delivered 12% (= PARTIAL)
Missed
- Guided 64% Gross Margin → delivered 56% (= MISS)
- Guided 11% Tax Rate → delivered 11% (= BEAT)
Investor Presentation filed with BSE, NSE: NATHBIOGEN. Summary written with AI assistance from the document.
Nath Bio-Genes (India) Ltd: key numbers
- Share price
- ₹140.13
- Market cap
- ₹266.3 Cr
- Revenue (annual)
- ₹445.1 Cr
- Net profit (annual)
- ₹41.63 Cr
- P/E (TTM)
- 7.3×Sector 28.6×
- Promoter holding
- 45.60%+0.00% QoQ
- FII holding
- 0.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nath Bio-Genes (India) Ltd
All →Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd held its 33rd AGM on September 24, 2026. Shareholders approved all five resolutions, including a final dividend of ₹2/- per share.
Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd issued notice for its 33rd Annual General Meeting, to be held on September 24, 2026, alongside the Annual Report for FY2025-26.
Nath Bio-Genes (India) ED Probe / Tax Survey
SEBI has initiated a forensic audit of Nath Bio-Genes (India) Ltd for financial years 2020-21 to 2025-26. CNK & Associates LLP has been appointed as the forensic auditor.
- Execution
- FY 2020-21 to 2025-26
Nath Bio-Genes (India) Q1 FY27 Results: Net Profit ₹32.3 Cr, Up 14.1% YoY
Nath Bio-Genes (India) Ltd reported revenue from operations of ₹328.4 Cr (+15.8% YoY) and net profit of ₹32.3 Cr (+14.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹32.3 Cr · +14.1% YoY
Nath Bio-Genes (India) Other Announcement
Nath Bio-Genes (India) Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b). This disclosure provides the updated distribution of shareholding across various investor categories.
Nath Bio-Genes (India) Board Meeting Date
Nath Bio-Genes (India) Ltd has scheduled a board meeting for 29th July 2026 to consider and approve its unaudited financial results for the June quarter.